Joint development of antibody therapeutics and diagnostic products for infectious diseases (AI Bio)
First written in FY2021-Q3. 3 of 6 entries say "Advanced", first in FY2021. Latest entry: FY2025-H1.
No other company in this theme has enough history to compare yet.
- FY2025-H1AdvancedAnnual report
「AI Bio Co., Ltd. (our subsidiary) SML Biopharm Co., Ltd. Exclusive license agreement 20 June 2024 From 20 June 2024 to 19 June 2034 License to use antibody gene sequences (Note) We receive an upfront contractual fee as consideration. The agreement also provides for milestone payments linked to development progress and royalty income linked to sales after the product is launched.」
AI Bio entered into an exclusive license agreement with SML Biopharm for antibody gene sequences, providing for an upfront contractual fee, milestone payments linked to development progress and royalty income after the start of sales. The agreement runs from 20 June 2024 to 19 June 2034. - FY2024SoftenedAnnual report
「As research and development funding will be reduced following the formation of the subsidiary, the company temporarily suspended the planned nonclinical studies using cynomolgus monkeys and will focus on early out-licensing using test results obtained to date.」
Following the reduction in research and development funding associated with making AI Bio a subsidiary, infectious-disease antibody development discontinued the planned nonclinical study in cynomolgus monkeys and shifted its focus to early out-licensing. - FY2023ReframedAnnual report
「We received notice from ABCONTEK that, due to its management circumstances, it would be difficult for the company to continue bearing AI Bio's research and development expenses. As our effective control over AI Bio's management increased as a result of changes in the number of directors and audit & supervisory board members, among other measures, we decided to make AI Bio a subsidiary.」
The joint development platform for antibody drugs and diagnostic reagents for infectious diseases was reorganised, with AI Bio changed from an equity-method affiliate to a subsidiary following ABCONTEK's difficulty in bearing the funding burden. - FY2022-Q3AdvancedAnnual report
「AI BIO has obtained a license to practice antibodies against the virus that causes severe fever with thrombocytopenia syndrome (SFTS), a tick-borne infectious disease, and is conducting research and development aimed at commercialising therapeutic antibody drugs. It is currently manufacturing master cell banks (MCBs) and working cell banks (WCBs) at a contract development and manufacturing organisation (CDMO), while developing antibody production and manufacturing processes, and has reached the stage at which it can conduct preclinical studies in cynomolgus monkeys.」
AI BIO's development of antibody drugs for infectious diseases has progressed to the stage at which cell-bank manufacturing, antibody production and manufacturing-process development, and preclinical studies in cynomolgus monkeys can be conducted following acquisition of the license to practice SFTS virus antibodies. - FY2021AdvancedAnnual report
「Name AI Bio Co., Ltd. Capital ¥20 million Date established February 2021 (planned) Equity participation Immuno-Biological Laboratories Co.,Ltd.: 49% Abcontek Inc.: 51%」
The establishment, capital, formation date and equity participation of AI Bio, the joint development platform for antibody drugs and diagnostic reagents for infectious diseases, have been specified. - FY2021-Q3First statedAnnual report
「The parties plan to begin joint development aimed at commercializing a therapeutic antibody drug candidate with high neutralizing activity developed by ABCONTEK Co. The joint venture's future activities are planned to focus on developing drugs and diagnostic products for emerging infectious diseases, not limited to SFTS and COVID-19. Name: AI Bio Co., Ltd. Capital: ¥20 million Date of establishment: February 2021 (scheduled) Ownership ratio: Immuno-Biological Laboratories Co.,Ltd.: 49% Abcontek Inc.: 51%」
Through the joint venture AI Bio with ABCONTEK Co., the company plans to jointly develop therapeutic antibody drug and diagnostic product candidates for emerging infectious diseases, including SFTS and COVID-19. The joint venture was scheduled to be established in February 2021, with ownership ratios of 49% for the company and 51% for ABCONTEK Co.